The Myasthenia gravis, etiology, pathophysiology & therapeutical approaches team, led by Rozen Le Panse at the Institute of Myology’s Myology Research Centre, has developed a new experimental murine model of myasthenia gravis (N-EAMG) that is at least as effective as the classic experimental model (C-EAMG) and offers several advantages. N-EAMG:
- is better suited to animal welfare,
- is characterised by the production of T-AChR and m-AChR antibodies, like C-EAMG,
- also has altered transmission in the NMJ,
- presents symptoms similar to those observed in C-EAMG, but with a more rapid onset.
This model can replace the classical model in preclinical and fundamental research.
